Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Licenses Antibody Engineering Tech to argenx
October 7, 2020
- Armed with Enerzair, Novartis Looks to Establish Leading Position in Respiratory Arena
October 6, 2020
- Crysvita Approved in Europe for Adult XLH: Kyowa Kirin
October 6, 2020
- Nihon Chouzai’s Standard Formulary Service Fully Up and Running
October 5, 2020
- Axcelead, Kyowa Kirin Join Forces to Develop Small-Molecule Drugs
October 5, 2020
- Lilly’s Baqsimi Hits Japan Market, 1st Glucagon Nasal Powder
October 5, 2020
- AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
- Chugai Seeks Label Expansion for FoundationOne as CDx for Pemigatinib, Larotrectinib
October 5, 2020
- Kyowa Kirin Commences Japan PII of Zandelisib for Indolent B-Cell Non-Hodgkin’s Lymphoma
October 5, 2020
- Novartis’ Tabrecta Hits Snag in Japan on Hospitals’ CDx Reimbursement Issue
October 2, 2020
- Maruishi to Discontinue Precedex after Pfizer Pact Expires
October 2, 2020
- UCB Japan Goes Solo on E Keppra Marketing as Otsuka Deal Ends
October 2, 2020
- Fujifilm to Manufacture VLP Therapeutics’ COVID-19 Vaccine
October 2, 2020
- ASKA, Kyorin to Jointly Develop Benign Prostatic Hyperplasia Drug
October 1, 2020
- Eisai, Seikagaku Tie Up on Osteoarthritis Med in South Korea
October 1, 2020
- Mitsubishi Tanabe Recalls Theodur on Failed Dissolution Test
October 1, 2020
- Shionogi Grabs Global Rights for Univ. of Tokyo Spin-Off’s Novel S. Pneumoniae Nasal Vaccine
October 1, 2020
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Fetroja Approved for Nosocomial Pneumonia in US
September 30, 2020
- Fujifilm Kyowa Kirin’s Avastin Biosimilar Approved in Europe
September 30, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…